Background: Treatment of non-clear cell RCC remains controversial despite several recent
Introduction
Over the past 12 years, the therapeutic arsenal against renal cell carcinoma (RCC) has widely expanded, with median overall survival increasing to almost 30 months in recent studies 1 
.
Prospective studies have shown that targeted therapy (TT) increases overall survival (OS) in metastatic clear cell, but the benefit in the other subtypes remains unclear.
Chromophobe renal cell carcinoma (ChRCC) is the second commonest form of non clear cell RCC (nccRCC) (4-6%) after papillary RCC (10-15%) 2 . Systemic therapy targeting VEGF and mTOR pathways have shown some efficacy in nccRCC, but to date little is known about the activity of monoclonal antibody directed against the program death 1 (PD 1)/ program death ligand 1 (PDL 1) pathway 3 , and newer VEGF TT 4 . Indeed, two randomized studies investigated targeted therapy in a pool of mixed non clear cell histologies 5, 6 and few prospective single arm trial (RAPTOR 7 , SUPAP 8 ) focus on papillary RCC.
First described by Thoenes in 1985 9 , ChRCC probably derived from the intercalated cells of the collecting duct system. Surgical cohorts suggest that localized ChRCC displays a more favorable prognosis than papillary or clear cell RCC (ccRCC) with only 1.5% -8.6% of patients developing recurrence or metastasis 10, 11 and a specific mortality around 2% 12, 13 .
Most of the data about metastatic ChRCC (mChRCC) comes from retrospective small series (3 to 37 patients) or rare phase 2 studies enrolling a heterogeneous population of nccRCC so then no standard of care is defined in ESMO 14 and NCCN guidelines 15 for mChRCC patients. In our study, we identified a large cohort of mChRCC to describe clinical outcomes with the use of TT.
Methods

Study design and population
In 2012, we initiated a retrospective chart review of mChRCC patients treated within the French and the objective response rate (ORR) defined as CR/PR, SD or PD were described. The latter was compared between the 2 classes of targeted therapies by a Fisher's exact test. The time to failure (TTF) was defined as the time from the date of first-line therapy to discontinuation of treatment for any reason, including disease progression, treatment toxicity, and death. Patients with no treatment failure were censored at the date of last follow up. Overall Survival (OS) was defined as the time from the first-line therapy to death. Patients alive were censored at the date of last follow-up. These 2 time-to-events were estimated by the Kaplan-Meier (KM) method and median with its 95% confidence interval (CI) was reported. We compared TTF and OS between (i) IMDC prognostic groups (log-rank test) and (ii) targeted therapies (AA and mTOR) (stratified log-rank test). For the latter, no interpretation can be done based on the KM estimation considering the observational type of this study. The cut-off date for the analyses was December 31 2015. The statistical analyses were done with SAS software 9.4. (SAS Institute).
Results
Overall mChRCC cohort
We collected data from 91 mChRCC patients from 26 centers in 4 countries (France, UK, Italy and Australia) ( Figure 1 
Response rate
Among patients treated by targeted therapy, the response were: CR: 1.9% (n=1), PR: 23.1%
(n=12), SD: 44.2% (n=23) and PD: 30.8% (n=16) (9 had missing data) ( 
Time to Treatment Failure
The median TTF from the date of first-line therapy for mChRCC was 7.2 months (95%CI: 4.1-9.5) with 61 events. Median TTF was 8.7 months (95%CI: 5.2-10.9) and 1.9 months (95%CI:
1.0-6.0) in patients treated with AA and mTOR inhibitors, respectively ( Figure 2A In our study, OS was 20.8 months (95%CI: 11.6-35.2) for patients treated with TT, and median OS from diagnosis of metastatic disease for the 90 patients was 37.9 months (CI95%: 21.4-46.8).
Our work is not without limitations inherent to its retrospective nature. Our work is not without To our knowledge, our cohort is the largest series of mChRCC treated with TT, providing a benchmark for future trials in this rare disease. Unfortunately, each of the recent prospective trials investigating nccRCC failed to include more than 15 mChRCC 5, 6, 18 . We report on 61 mChRCC treated with TT within a collaborative groups to provide valuable insight into rare renal tumors. However the weakness of the retrospective design limits results interpretation. Certainly, VEGF inhibition is a reasonable front line and mTOR inhibitors provides clinical benefits to some patients.
Conclusion
Metastatic ChRCC is a rare entity with no specific TT recommended. We describe the largest cohort, to date, of mChRCC treated with TT and illustrate the ability of an academic consortium to provide unique information on rare histologies. Emerging data from the genomic landscape of ChRCC may provide new insights into novel druggable targets in these patients 27 . Table 1 
